NHIA Member Home
Find a Provider

News Category: Infusion News

NHIA Releases Infusion Industry Trends Report

  • March 11, 2026
The National Home Infusion Association (NHIA) is releasing Infusion Industry Trends, the latest assessment of the home and alternate site infusion industry’s market position. Based on claims data from a 3-year timeframe, this focused analysis shows how the industry is evolving across therapy categories and payor environments.

NHIF Announces Finalists for 2026 Outstanding Abstract Achievement Award

  • March 10, 2026
The National Home Infusion Foundation (NHIF) announces the finalists for its Outstanding Abstract Achievement Award for 2026. The authors of the following 4 poster abstracts will present an overview of their research project and summarize their findings during a special clinical webinar and a panel of judges will select the award recipient.

CMS Clarifies Pharmacy Enrollment Pathway Under Nationwide DMEPOS Moratorium

  • March 3, 2026
The National Home Infusion Association (NHIA) has received clarification from CMS regarding enrollment options for home infusion pharmacies under the current nationwide DMEPOS enrollment moratorium.

NHIA Testifies at Congressional Hearing as Momentum Builds to Fix Medicare’s Home Infusion Benefit

January 8, 2026

National Home Infusion Association (NHIA) President and CEO Connie Sullivan testified today before the House Energy and Commerce Committee Subcommittee on Health in support of the Preserving Patient Access to Home Infusion Act (H.R. 2172). The hearing marked a major milestone for the legislation, with Members from both parties emphasizing the need to strengthen Medicare and remove barriers that keep seniors from receiving clinically appropriate infusion care at home.

Read More »

Call for NHIA Board Member Candidates

January 6, 2026

NHIA is accepting applications for members of the association’s Board of Directors. Board members serve 3-year terms as representatives for the NHIA member organization. Seats are open to provider members and are assigned at the organization level. Two seats are currently available for hospital providers (a provider that is wholly owned and operated as part of an acute care system).

Read More »

A Vial Access Device for Facilitated Subcutaneous Immunoglobulin 10% Using Modular Innovation Principles and a Patient-Centric Design

December 8, 2025

Full text | Download pdf

https://doi.org/10.70776/QHAL9260

Kimberly Duff, RN, BSN Clinical Sciences, R&D Takeda Development Center Americas, Inc. | Stefan Holzner, PhD* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Madeleine Gibson, MSIE* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Seth Jones, BSc* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Scott Ariagno, MSc* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. *Affiliation at the time of the study

Facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) is packaged as a dual-vial unit of immunoglobulin G 10% (labelled ‘IG’) and recombinant human hyaluronidase (rHuPH20; labelled ‘HY’) for use as a prescribed immunoglobulin treatment for patients with primary or secondary immunodeficiency and chronic inflammatory demyelinating polyradiculoneuropathy.

Read More »

Optimizing Subcutaneous Immunoglobulin Therapy: A Modified Delphi Study on Supply Management and Best Practices in the U.S. Health Care System

December 8, 2025

Full text | Download pdf

https://doi.org/10.70776/ZJVE7679

Devin Wall, RN KORU Medical Systems | Elizabeth M. Younger, CRNP, PhD Johns Hopkins University School of Medicine | Kelvin Shaw, MD Allergy and ENT Associates | Chris Pratt, PharmD CVS Suzanne Strasters, FNP-C GC Biopharma | Sam Mihelich, PharmD NuFactor Specialty Pharmacy | Will Holland, PharmD Realo Specialty Care | Sarah Taylor, RN Realo Specialty Care | Kolleen Casey, BSN KH Nursing Services | Nicole Graves, RN RxCrossroads

Subcutaneous immune globulin (SCIG) therapy is a flexible, patient-centered alternative to intravenous immune globulin (IVIG). While increasingly popular in home and specialty infusion care, managing the ancillary supplies for SCIG therapy remains complex. Current literature offers general guidance on SCIG administration but lacks detailed consensus on best practices for supply management, infusion site selection, and training requirements.

Read More »

Utilization and Tolerability of Crizanlizumab In Adult Alternate Infusion Site Patients: A Descriptive Retrospective Cohort Study

December 4, 2025

Full text | Download pdf

https://doi.org/10.70776/WMSV6374

Kascha Brown PharmD, MS Option Care Health | Maria Giannakos, PharmD, MBA, BCPS, BCSCP, FNHIA, Option Care Health | Christopher Roy PharmD, BCSCP Option Care Health | Annemarie Hocking PharmD Option Care Health

Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by vaso-occlusive crises (VOCs), leading to significant morbidity and health care utilization. Crizanlizumab, a P-selectin inhibitor, was approved in 2019 to reduce the frequency of VOCs. Limited data are available on the utilization and tolerability of crizanlizumab administered in home and alternate infusion site (AIS) settings.

Read More »

NHIA Members Hold 130+ Congressional Meetings in Support of the Preserving Patient Access to Home Infusion Act

November 7, 2025

The National Home Infusion Association (NHIA) today held its annual Advocacy in Action Day, during which association members and patients met with Members of Congress and their staff to advocate for a fix to the Medicare home infusion coverage gap. Over the course of the event, NHIA members held more than 130 meetings in support of the Preserving Patient Access to Home Infusion Act (H.R. 2172 / S. 1058).

Read More »

NHIA Comments on Proposed EIP LCD

September 8, 2025

NHIA submitted comments to the DME MAC medical directors regarding their proposed local coverage determination (LCD) for external infusion pumps (EIPs). DL33794 would expand Medicare Part B coverage for blinatumomab (Blimcyto®, Amgen) for certain indications.

Read More »

Joe Fiandra Access to Home Infusion Act of 2025 (H.R. 4993) Bill Summary

August 25, 2025

The Joe Fiandra Access to Home Infusion Act (H.R. 5397) was first introduced in the House of Representatives in September of 2023, and re-introduced on August 19, 2025 by Rep. Brian Fitzpatrick (PA-01). The bill mirrors a 2020 proposed rule from the Centers for Medicare and Medicaid Services (CMS) to modify the DMEPOS external infusion pump benefit.

Read More »

NHIA Releases White Paper on Home Parenteral Nutrition Cost Trends

August 5, 2025

The National Home Infusion Association (NHIA) has released a white paper examining the economic challenges facing home parenteral nutrition (HPN) services. The report, “Ensuring Sustainable Access to Home Parenteral Nutrition (PN): The Cost Crisis and Path Forward,” documents cost trends and reimbursement patterns affecting this therapy.

Read More »

Implementation and Pilot Evaluation of A Pharmacist-Led Optimization Tool for Subcutaneous Immune Globulin Administration in the Home Setting

July 31, 2025

Full text | Download pdf

https://doi.org/10.70776/SCYQ3388

Katie Laskin, PharmD, BCSCP, FNHIA, IgCP, CBSC Yale New Haven Health Home Infusion | Jill Yusko, RPh. Yale New Haven Health Home Infusion | Jennifer Bunk, PharmD Yale New Haven Health Home Infusion | Gene B. Decaminada BS Pharm, RPh, FNHIA, FCPA Yale New Haven Health Home Infusion | Nicholas LaRiviere PharmD, MBA, BCGP Yale New Haven Health Home Infusion

This study aimed to develop a standardized method and timeline for home infusion pharmacists to assess subcutaneous immune globulin (SCIG) regimens and perform interventions to optimize infusions based on patient tolerance and preference. A tool was built within the electronic patient management platform at a health system-affiliated home infusion pharmacy to aid in standardizing patient assessments and capturing interventions. This tool was tested over a period of 2 months.

Read More »

A Descriptive Cross-Sectional Study of Patient Experience Among Home Infusion Patients Administering Immune Globulin: A Comparison of Satisfaction Between IV and SC Administration

July 30, 2025

Full text | Download pdf

https://doi.org/10.70776/XISU1319

Danell Haines, PhD Research Consultant | Michelle C. Simpson, PharmD, BCSCP, MWC National Home Infusion Association

Immune globulin (Ig) preparations are administered to patients to treat a variety of diagnoses. Originally developed to increase and maintain IgG levels in patients with antibody deficiencies, immune globulin preparations are also part of the treatment plan for autoimmune or connective tissue disorders, neurologic diseases, and inflammatory conditions. Due to the growth of Ig therapy in the home, there is a need for more valid and comprehensive patient satisfaction data about the home infusion experience that can be used to improve patient care and outcomes. The objective of this research is to analyze patient satisfaction survey data from the National Home Infusion Foundation and evaluate patient satisfaction similarities and differences between 2 groups: intravenous and subcutaneous administration of immune globulin.

Read More »

NHIA Testifies at Congressional Hearing as Momentum Builds to Fix Medicare’s Home Infusion Benefit

January 8, 2026

National Home Infusion Association (NHIA) President and CEO Connie Sullivan testified today before the House Energy and Commerce Committee Subcommittee on Health in support of the Preserving Patient Access to Home Infusion Act (H.R. 2172). The hearing marked a major milestone for the legislation, with Members from both parties emphasizing the need to strengthen Medicare and remove barriers that keep seniors from receiving clinically appropriate infusion care at home.

Read More »

Call for NHIA Board Member Candidates

January 6, 2026

NHIA is accepting applications for members of the association’s Board of Directors. Board members serve 3-year terms as representatives for the NHIA member organization. Seats are open to provider members and are assigned at the organization level. Two seats are currently available for hospital providers (a provider that is wholly owned and operated as part of an acute care system).

Read More »

A Vial Access Device for Facilitated Subcutaneous Immunoglobulin 10% Using Modular Innovation Principles and a Patient-Centric Design

December 8, 2025

Full text | Download pdf

https://doi.org/10.70776/QHAL9260

Kimberly Duff, RN, BSN Clinical Sciences, R&D Takeda Development Center Americas, Inc. | Stefan Holzner, PhD* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Madeleine Gibson, MSIE* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Seth Jones, BSc* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. | Scott Ariagno, MSc* Pharmaceutical Sciences, R&D Takeda Development Center Americas, Inc. *Affiliation at the time of the study

Facilitated subcutaneous immunoglobulin 10% (fSCIG 10%) is packaged as a dual-vial unit of immunoglobulin G 10% (labelled ‘IG’) and recombinant human hyaluronidase (rHuPH20; labelled ‘HY’) for use as a prescribed immunoglobulin treatment for patients with primary or secondary immunodeficiency and chronic inflammatory demyelinating polyradiculoneuropathy.

Read More »

Optimizing Subcutaneous Immunoglobulin Therapy: A Modified Delphi Study on Supply Management and Best Practices in the U.S. Health Care System

December 8, 2025

Full text | Download pdf

https://doi.org/10.70776/ZJVE7679

Devin Wall, RN KORU Medical Systems | Elizabeth M. Younger, CRNP, PhD Johns Hopkins University School of Medicine | Kelvin Shaw, MD Allergy and ENT Associates | Chris Pratt, PharmD CVS Suzanne Strasters, FNP-C GC Biopharma | Sam Mihelich, PharmD NuFactor Specialty Pharmacy | Will Holland, PharmD Realo Specialty Care | Sarah Taylor, RN Realo Specialty Care | Kolleen Casey, BSN KH Nursing Services | Nicole Graves, RN RxCrossroads

Subcutaneous immune globulin (SCIG) therapy is a flexible, patient-centered alternative to intravenous immune globulin (IVIG). While increasingly popular in home and specialty infusion care, managing the ancillary supplies for SCIG therapy remains complex. Current literature offers general guidance on SCIG administration but lacks detailed consensus on best practices for supply management, infusion site selection, and training requirements.

Read More »

Utilization and Tolerability of Crizanlizumab In Adult Alternate Infusion Site Patients: A Descriptive Retrospective Cohort Study

December 4, 2025

Full text | Download pdf

https://doi.org/10.70776/WMSV6374

Kascha Brown PharmD, MS Option Care Health | Maria Giannakos, PharmD, MBA, BCPS, BCSCP, FNHIA, Option Care Health | Christopher Roy PharmD, BCSCP Option Care Health | Annemarie Hocking PharmD Option Care Health

Sickle cell disease (SCD) is a hereditary hemoglobinopathy characterized by vaso-occlusive crises (VOCs), leading to significant morbidity and health care utilization. Crizanlizumab, a P-selectin inhibitor, was approved in 2019 to reduce the frequency of VOCs. Limited data are available on the utilization and tolerability of crizanlizumab administered in home and alternate infusion site (AIS) settings.

Read More »

NHIA Members Hold 130+ Congressional Meetings in Support of the Preserving Patient Access to Home Infusion Act

November 7, 2025

The National Home Infusion Association (NHIA) today held its annual Advocacy in Action Day, during which association members and patients met with Members of Congress and their staff to advocate for a fix to the Medicare home infusion coverage gap. Over the course of the event, NHIA members held more than 130 meetings in support of the Preserving Patient Access to Home Infusion Act (H.R. 2172 / S. 1058).

Read More »

NHIA Comments on Proposed EIP LCD

September 8, 2025

NHIA submitted comments to the DME MAC medical directors regarding their proposed local coverage determination (LCD) for external infusion pumps (EIPs). DL33794 would expand Medicare Part B coverage for blinatumomab (Blimcyto®, Amgen) for certain indications.

Read More »

Joe Fiandra Access to Home Infusion Act of 2025 (H.R. 4993) Bill Summary

August 25, 2025

The Joe Fiandra Access to Home Infusion Act (H.R. 5397) was first introduced in the House of Representatives in September of 2023, and re-introduced on August 19, 2025 by Rep. Brian Fitzpatrick (PA-01). The bill mirrors a 2020 proposed rule from the Centers for Medicare and Medicaid Services (CMS) to modify the DMEPOS external infusion pump benefit.

Read More »

NHIA Releases White Paper on Home Parenteral Nutrition Cost Trends

August 5, 2025

The National Home Infusion Association (NHIA) has released a white paper examining the economic challenges facing home parenteral nutrition (HPN) services. The report, “Ensuring Sustainable Access to Home Parenteral Nutrition (PN): The Cost Crisis and Path Forward,” documents cost trends and reimbursement patterns affecting this therapy.

Read More »

Implementation and Pilot Evaluation of A Pharmacist-Led Optimization Tool for Subcutaneous Immune Globulin Administration in the Home Setting

July 31, 2025

Full text | Download pdf

https://doi.org/10.70776/SCYQ3388

Katie Laskin, PharmD, BCSCP, FNHIA, IgCP, CBSC Yale New Haven Health Home Infusion | Jill Yusko, RPh. Yale New Haven Health Home Infusion | Jennifer Bunk, PharmD Yale New Haven Health Home Infusion | Gene B. Decaminada BS Pharm, RPh, FNHIA, FCPA Yale New Haven Health Home Infusion | Nicholas LaRiviere PharmD, MBA, BCGP Yale New Haven Health Home Infusion

This study aimed to develop a standardized method and timeline for home infusion pharmacists to assess subcutaneous immune globulin (SCIG) regimens and perform interventions to optimize infusions based on patient tolerance and preference. A tool was built within the electronic patient management platform at a health system-affiliated home infusion pharmacy to aid in standardizing patient assessments and capturing interventions. This tool was tested over a period of 2 months.

Read More »

A Descriptive Cross-Sectional Study of Patient Experience Among Home Infusion Patients Administering Immune Globulin: A Comparison of Satisfaction Between IV and SC Administration

July 30, 2025

Full text | Download pdf

https://doi.org/10.70776/XISU1319

Danell Haines, PhD Research Consultant | Michelle C. Simpson, PharmD, BCSCP, MWC National Home Infusion Association

Immune globulin (Ig) preparations are administered to patients to treat a variety of diagnoses. Originally developed to increase and maintain IgG levels in patients with antibody deficiencies, immune globulin preparations are also part of the treatment plan for autoimmune or connective tissue disorders, neurologic diseases, and inflammatory conditions. Due to the growth of Ig therapy in the home, there is a need for more valid and comprehensive patient satisfaction data about the home infusion experience that can be used to improve patient care and outcomes. The objective of this research is to analyze patient satisfaction survey data from the National Home Infusion Foundation and evaluate patient satisfaction similarities and differences between 2 groups: intravenous and subcutaneous administration of immune globulin.

Read More »
News Archive